Download Library

INVESTORS & MEDIA

INVESTORS
& MEDIA

 
Download Library
Document Type
Safety and preliminary clinical activity of REGN1979, an anti-CD20 × anti-CD3 bispecific antibody, in patients with B-NHL previously treated with CD20-directed antibody therapy
Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody Cemiplimab (REGN2810) Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies
View Presentation
Presentations - Featured Presentation
DUPIXENT Full Prescribing Information
Media Kit
URL
N/A
KEVZARA Full Prescribing Information
Media Kit
URL
N/A
View 2 Macula 2017 Presentation
Regeneron ASCO 2017 Presentation
NLA 2017
2016 Form 10-K
Annual Reports
1
...
NextLast
= add file to Briefcase